Table 3 Demographic and clinical characteristics of participants by TyG
| Â | TyG 1 | TyG 2 | TyG 3 | TyG 4 | P |
|---|---|---|---|---|---|
Age (years) | 58.11 ± 10.94 | 57.74 ± 11.55 | 60.03 ± 11.86 | 60.34 ± 12.37 | 0.034 |
Gender (male) | 139 (61.0) | 142 (62.3) | 138 (60.5) | 142 (62.3) | 0.972 |
Smoke [(n%)] | 91 (39.9) | 92 (40.4) | 107 (46.9) | 91 (39.9) | 0.343 |
HT [(n%)] | 120 (52.6) | 123 (53.9) | 141 (61.8) | 147 (64.5) | 0.023 |
DM [(n%)] | 22 (9.6) | 50 (21.9) | 76 (33.3) | 117 (51.3) |  < 0.001 |
CHD [(n%)] | 103 (45.2) | 112 (49.1) | 120 (52.6) | 138 (60.5) | 0.009 |
BMI (kg/m2) | 25.91 ± 2.65 | 25.98 ± 2.90 | 25.85 ± 2.76 | 26.35 ± 2.90 | 0.228 |
SBP (mmHg) | 129.89 ± 16.54 | 132.12 ± 18.32 | 134.89 ± 19.97 | 131.41 ± 20.07 | 0.037 |
DBP (mmHg) | 79.93 ± 12.83 | 80.60 ± 12.78 | 80.33 ± 13.56 | 79.20 ± 13.15 | 0.688 |
ALT (U/L) | 21.80 (16.00,29.70) | 22.55 (16.20,30.68) | 26.85 (18.25,34.15) | 26.05 (18.70,34.50) |  < 0.001 |
AST (U/L) | 21.50 (18.00, 26.10) | 22.50 (18.40, 28.30) | 23.30 (18.50, 29.28) | 23.40 (18.30, 30.60) | 0.039 |
Scr (mmol/L) | 67.00 (58.00, 77.00) | 67.50 (59.00, 77.00) | 65.18 (58.82, 75.92) | 68.00 (56.25, 78.00) | 0.699 |
TC (mmol/L) | 3.87 (3.26, 4.73) | 4.13 (3.57, 5.01) | 4.49 (3.64, 5.35) | 4.58 (3.75, 5.41) |  < 0.001 |
TG (mmol/L) | 1.13 (0.98, 1.27) | 1.48 (1.29, 1.71) | 1.94 (1.65, 2.20) | 2.53 (2.02, 2.98) |  < 0.001 |
HDL-C (mmol/L) | 1.19 (1.00, 1.40) | 1.08 (0.92, 1.29) | 1.05 (0.95, 1.20) | 1.02 (0.88, 1.17) |  < 0.001 |
LDL-C (mmol/L) | 2.10 (1.56, 2.60) | 2.28 (1.89, 2.75) | 2.40 (1.87, 2.92) | 2.42 (1.85, 2.92) |  < 0.001 |
FBG (mmol/L) | 5.06 (4.63, 5.45) | 5.39 (4.85, 6.25) | 5.72 (5.16,6.90) | 7.15 (5.81, 8.59) |  < 0.001 |
Anti-diabetic drugs[(n%)] | 16 (7.0) | 39 (17.1) | 72 (31.6) | 109 (47.8) |  < 0.001 |
Lipid-lowering drugs[(n%)] | 58 (25.4) | 65 (28.5) | 73 (32.0) | 82 (36.0) | 0.084 |
TyG | 8.39 ± 0.20 | 8.78 ± 0.83 | 9.09 ± 0.99 | 9.57 ± 0.27 |  < 0.001 |
AF [(n%)] | 38 (16.7) | 38 (16.7) | 520 (22.8) | 76 (33.3) |  < 0.001 |